No effects of a 6‐week intervention with a glucagon‐like peptide‐1 receptor agonist on pancreatic volume and oedema in obese men without diabetes

• Published in: Diabetes, obesity & metabolism obesity & metabolism, 2020-10, Vol.22 (10), p.1837-1846
• Main Authors: Svane, Maria S., Johannesen, Helle H., Martinussen, Christoffer, Bojsen‐Møller, Kirstine N., Hansen, Martin Lundsgaard, Hansen, Adam E., Deacon, Carolyn F., Hartmann, Bolette, Keller, Sune H., Klausen, Thomas L., Loft, Annika, Kjaer, Andreas, Madsbad, Sten, Löfgren, Johan, Holst, Jens J., Wewer Albrechtsen, Nicolai J.
• Format: Article
• Language: English
• Subjects: Agonists; antiobesity drug clinical trial GLP‐1 analogue; Body mass index; Deoxyribonucleic acid; Diabetes; Diabetes mellitus; DNA; DNA biosynthesis; Edema; Glucagon; Lipase; Magnetic resonance imaging; Mens health; Obesity; Pancreas; Peptides; Positron emission tomography; Titration
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/dom.14106

Aim To investigate the effect of a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), liraglutide, on pancreatic volume, oedema, cellularity and DNA synthesis in humans. Materials and Methods We performed an open‐label study in 14 obese men (age 38 ± 11 years, body mass index 32 ± 4 kg/m2) without diabetes. Subjects were examined at baseline, during titration (week 4) of liraglutide towards 3.0 mg/day, and 2 weeks after steady‐state treatment (week 6) of a final dose of liraglutide. The primary endpoint was pancreatic volume determined by magnetic resonance imaging. Secondary endpoints included pancreatic oedema and cellularity, positron emission tomography‐based [18F]fluorothymidine (FLT) uptake (DNA synthesis) and plasma pancreatic enzymes. Results Plasma amylase (+7 U/L [95% confidence intervals 3‐11], P